CATALOGO DEI PRODOTTI DELLA RICERCA

BELLINATO, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.870
NA - Nord America 3.515
AS - Asia 2.936
SA - Sud America 501
AF - Africa 199
OC - Oceania 47
Totale 11.068
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.410
RU - Federazione Russa 1.764
SG - Singapore 1.363
IT - Italia 782
CN - Cina 484
BR - Brasile 399
HK - Hong Kong 296
VN - Vietnam 269
DE - Germania 241
GB - Regno Unito 217
IE - Irlanda 163
FI - Finlandia 145
SE - Svezia 140
FR - Francia 116
KR - Corea 98
NL - Olanda 77
IN - India 74
ID - Indonesia 67
TR - Turchia 59
CA - Canada 48
ES - Italia 48
TG - Togo 47
JP - Giappone 43
MX - Messico 43
NG - Nigeria 42
AU - Australia 41
BJ - Benin 40
PL - Polonia 34
AR - Argentina 32
BD - Bangladesh 27
ZA - Sudafrica 27
AT - Austria 25
IQ - Iraq 20
EC - Ecuador 19
SA - Arabia Saudita 18
IR - Iran 17
MY - Malesia 16
CH - Svizzera 15
CL - Cile 15
UA - Ucraina 14
PH - Filippine 11
PK - Pakistan 11
CO - Colombia 10
DK - Danimarca 10
HR - Croazia 9
UZ - Uzbekistan 9
DZ - Algeria 8
TN - Tunisia 8
VE - Venezuela 8
BE - Belgio 7
JO - Giordania 7
NP - Nepal 7
PT - Portogallo 7
RO - Romania 7
EG - Egitto 6
GR - Grecia 6
MA - Marocco 6
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
HU - Ungheria 5
IL - Israele 5
IS - Islanda 5
NZ - Nuova Zelanda 5
PY - Paraguay 5
BG - Bulgaria 4
BO - Bolivia 4
ET - Etiopia 4
KE - Kenya 4
BH - Bahrain 3
BY - Bielorussia 3
CZ - Repubblica Ceca 3
GD - Grenada 3
GE - Georgia 3
GH - Ghana 3
KZ - Kazakistan 3
LT - Lituania 3
NO - Norvegia 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
BN - Brunei Darussalam 2
DO - Repubblica Dominicana 2
HN - Honduras 2
JM - Giamaica 2
LB - Libano 2
LV - Lettonia 2
OM - Oman 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
TH - Thailandia 2
AD - Andorra 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DM - Dominica 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
Totale 11.053
Salva come PNG Salva come JPEG
Città #
Singapore 725
Moscow 631
Ashburn 580
Dallas 568
San Jose 499
Hong Kong 283
Chandler 267
Verona 184
Dublin 152
The Dalles 122
Munich 114
Ho Chi Minh City 104
New York 101
Beijing 93
Council Bluffs 93
Los Angeles 85
Helsinki 77
Milan 66
Hanoi 65
London 65
Jakarta 51
Lappeenranta 51
Lomé 47
Rome 43
Cotonou 40
Southend 39
Redondo Beach 37
São Paulo 37
Buffalo 35
Lawrence 34
Princeton 34
Abuja 33
Houston 31
Naples 30
Santa Clara 29
Amsterdam 28
Seattle 28
Tokyo 28
Warsaw 27
Bologna 26
Jacksonville 25
Sindelfingen 25
Wilmington 25
Washington 24
Chicago 23
Frankfurt am Main 23
Orem 23
Chennai 22
Nuremberg 21
Mexico City 19
Phoenix 19
Venice 19
Brooklyn 17
Istanbul 17
Montreal 17
Atlanta 16
Madrid 16
Sydney 16
Florence 14
Johannesburg 14
Tianjin 14
Kuala Lumpur 13
Mumbai 13
Xi'an 13
Boston 12
Enfield 12
Guangzhou 12
Rio de Janeiro 12
Shanghai 12
Turin 12
Belo Horizonte 11
Brasília 11
Toronto 11
Baghdad 10
Columbus 10
Haiphong 10
Manchester 10
Perth 10
Copenhagen 9
Da Nang 9
Denver 9
Dongguan 9
Esslingen am Neckar 9
Genoa 9
Palermo 9
Santiago 9
Tashkent 9
Trieste 9
Vienna 9
Jinan 8
Mersin 8
Stockholm 8
Vicenza 8
Ankara 7
Bari 7
Curitiba 7
Falkenstein 7
Pescara 7
Riyadh 7
Turku 7
Totale 6.365
Salva come PNG Salva come JPEG
Nome #
Il ruolo della vitamina D nella dermatite atopica 388
A systematic review of treatments for pityriasis lichenoides 329
Dietary supplements for lipedema 309
Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study 262
Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare 181
BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. 171
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 169
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 166
Polymorphisms, diet and nutrigenomics 165
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 157
Impact of the COVID-19 pandemic on melanoma diagnosis 156
Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis 155
Association between short-term exposure to environmental air pollution and atopic dermatitis flare in patients treated with dupilumab 151
A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis 150
Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature 150
Amicrobial Pustulosis of the Folds: Report of Three New Cases 135
Hypochondriasis and Personality Traits of Patients with Chronic Plaque Psoriasis 133
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study 130
Clinical Characteristics of Patients with Pustular Psoriasis: A Single-Center Retrospective Observational Study 129
Adrenergic urticaria successfully treated with omalizumab 129
Central Pain Sensitization in Patients with Chronic Plaque Psoriasis 127
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis 127
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease 125
Clinical profile and co-infections of urethritis in males 124
Comparative dermoscopy assessment of nevus-associated versus de novo in situ melanoma 122
Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis 122
Coexistence of scleromyxedema and Sneddon syndrome 121
Dermoscopic features of nevoid melanoma: a retrospective study 118
Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review 118
Price variability of TNF-α inhibitor biosimilars among European countries 117
Main nutritional deficiencies 114
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 113
Pretibial Dystrophic Epidermolysis Bullosa Successfully Treated with Upadacitinib: A Case Report 113
BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells 112
Clinical‐epidemiological aspects of the Monkeypox 2022 epidemic: a multicenter study by the Italian SIDeMaST Group of Sexually Transmitted, Infectious and Tropical Diseases 112
Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case-series 110
Diagnosis and Treatment of Infantile Hemangioma from the Primary Care Paediatricians to the Specialist: A Narrative Review 109
The transition from mild to moderate-to-severe chronic plaque psoriasis 109
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis 109
Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics 104
Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome 102
Consensus on the place in therapy of TNF-a inhibitors in the treatment of patients with chronic plaque psoriasis 101
Primary nodular localized cutaneous amyloidosis of the scalp associated with systemic lupus erythematosus 100
Awareness of obesity among patients with psoriasis 99
Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination 99
Managing the Patient with Psoriasis and Metabolic Comorbidities 98
Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report 98
Sezary syndrome with large cell transformation and T-follicular helper phenotype 98
The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events 97
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review 97
Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities 95
Predictors of subsequent primary melanoma: a case-control study 94
Lamivudine, Doravirine, and Cabotegravir downregulate the expression of Human Endogenous Retroviruses (HERVs), inhibit cell growth, and reduce invasive capability in melanoma cell lines 93
Dupilumab for recalcitrant Kimura disease 93
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis 91
Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs 90
Upadacitinib in refractory cutaneous pseudolymphoma: A case report 89
Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies 87
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines 87
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study 86
Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. 85
Generalized pustular psoriasis successfully treated with spesolimab: A case report 84
Dietary supplements for the management of COVID-19 symptoms 84
In vitro cell culture of amniotic fluid keratinocytes on amniotic membrane: the ideal tissue for repairing skin ulcers 83
Optimization of long-range PCR protocol to prepare filaggrin exon 3 libraries for PacBio long-read sequencing 83
Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis 83
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV2 infection and vaccination 82
Systematic study on nail plate assessment: differences in nail plate shape, thickness, power Doppler signal and scanning approach 81
Enhancing Skin Cancer Prevention and Awareness in the Italian Population: Insights from the “Save Your Skin” Screening Campaign 81
Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies 81
Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis 80
The Risk of COVID‐19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments 79
Polyphenols and Lactobacillus reuteri in oral health 75
Monkeypox virus infection: what dermatologist needs to know? 75
Validating methods for testing natural molecules on molecular pathways of interest in silico and in vitro 75
Cutaneous Adverse Reactions to SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis 75
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience 75
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules 75
Skin adverse reactions to Sars‐CoV‐2 vaccination: a relevant responsibility issue for dermatologists 73
Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis 71
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study 70
Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment 70
Novel loss-of-function variants in filaggrin exon 3 in patients with severe atopic dermatitis 69
Is risankizumab as needed administration a good option for patients with plaque psoriasis? 67
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort 65
X-linked genodermatoses from diagnosis to tailored therapy 64
Omics sciences and precision medicine in melanoma 61
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments 60
Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis 59
Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks 59
Long-term follow-up of Zoon balanitis: a retrospective cohort study 56
Neurothekeoma: a pediatric case report and literature review 56
Could Targeted Pharmacotherapies Exert a "Disease Modification Effect" in Patients with Chronic Plaque Psoriasis? 56
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis 55
Psoriasis: talking points from recent clinical trials 54
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 53
Scurvy as Presenting Sign of Anorexia Nervosa 52
Super Responder Profle Under Bimekizumab Treatment in Moderate‐to‐Severe Psoriasis: A Short Term Real‐Life Observation—IL PSO (Italian Landscape Psoriasis) 49
PsoBioVax: A multicentric Italian case–control study of the immunological response to anti‐SARS‐CoV‐2 vaccine among psoriatic patients under biological therapy 49
Corymbose Syphilis 46
Totale 10.685
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.295
article - articoli 40.295
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.590
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202121 0 0 0 0 0 0 0 0 0 4 13 4
2021/2022224 12 27 4 12 31 12 15 16 11 12 17 55
2022/20231.126 38 72 63 144 63 203 15 53 210 157 78 30
2023/2024940 59 64 97 102 82 166 67 57 16 44 108 78
2024/20252.473 119 104 125 379 118 145 227 112 376 192 167 409
2025/20266.310 423 480 439 870 1.731 378 682 468 470 369 0 0
Totale 11.209